Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the ...

Encoded Therapeutics chief medical officer Sal Rico said: “ETX101 represents a groundbreaking advancement in the therapeutic landscape for Dravet syndrome, with potential not only for seizure ...

The 12-month open-label extension of the PACIFIC trial demonstrated that bexicaserin significantly reduced seizure frequency in patients with developmental and epileptic encephalopathies while ...

The approach has had phenomenal success, with King’s laboratory uncovering possible therapies for Dravet syndrome, epilepsy, abdominal pain, and stroke. Dravet syndrome is a rare and life ...

Takeda’s experimental epilepsy drug soticlestat has failed not one but two phase 3 trials – in Dravet syndrome and Lennox-Gastaut syndrome – throwing the future of the programme in doubt.

Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...

stock shot up 70% in post-market trading Monday after the company reported positive results from studies for its drug STK-001 in the treatment of children and adolescents with Dravet syndrome, a ...

Treatment with cannabidiol led to improved seizure and nonseizure outcomes in patients with various forms of epilepsy, data show. The BECOME-TSC study evaluated outcomes of Epidiolex (Jazz ...

“What families and we as clinicians now want are medicines that go beyond reducing seizures to address the neurodevelopmental issues associated with Dravet syndrome, including giving patients ...

BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

The diagnosis of Dravet syndrome was adjudicated independently by the Epilepsy Study Consortium. The study treatment period was 16 weeks including a 4-week titration period and 12 weeks ...